CLASS III Device recall · Reported 2 Oct 2013 · FDA Enforcement Report

ABX Pentra Calcium CP Reagent recalled by Horiba Instruments

Horiba Instruments is recalling ABX Pentra Calcium CP Reagent. The recall was initiated on 6 Sep 2013 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot/Serial #(s): 014664503
Quantity recalled2,658 units ( 1240 US 1418 OUS )

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2280-2013
FDA event ID
66209
Recalling firm
Horiba Instruments, Irvine, CA
Classification
Class III
Status
Terminated
Recall initiated
6 Sep 2013
FDA classified
26 Sep 2013
Reported
2 Oct 2013
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Device Malfunction

Timeline

6 Sep 2013Recall initiated by company
26 Sep 2013Classified by FDA+20 days
2 Oct 2013Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

HORIBA Medical is informing all PENTRA 200 and PENTRA 400 customers of a potential for reporting incorrect calcium results when using the ABX PENTRA CALCIUM CP reagent.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

ABX PENTRA Calcium CP Reagent, Model # A11A01633 Calcium plays an essential role in many cell functions: intracellularly in muscle contraction and glycogen metabolism, extracellularly, in bone mineralization, in blood coagulation and in transmission of nerve impulses. Calcium is present in plasma in three forms: free, bound to proteins or complexed with anions as phosphate, citrate and bicarbonate. Under physiological conditions, calcium balance is determined by the relationship between calcium intake and calcium absorption and excretion. Urinary excretion is an important determinant of calcium retention in the body. Decreased total calcium levels can be associated with diseases of the bone apparatus (especially osteoporosis), kidney diseases (especially under dialysis), defective intestinal absorption and hypoparathyroidism. Increased total calcium can be measured in hyperparathyroidism, malignant diseases with metastases and sarcoidosis. Calcium measurements also help in monitoring of calcium supplementation mainly in the prevention of osteoporosis.

Where it was distributed

Worldwide Distribution - USA including the country of Canada.

Questions about this recall

Why was it recalled?

HORIBA Medical is informing all PENTRA 200 and PENTRA 400 customers of a potential for reporting incorrect calcium results when using the ABX PENTRA CALCIUM CP reagent.

Which lots are affected?

Lot/Serial #(s): 014664503

Where was it sold?

Worldwide Distribution - USA including the country of Canada.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Horiba Instruments

All 28

Other Hip & Knee Implants recalls

All 3,118